Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkaa270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections-authors' response.
J Antimicrob Chemother
September 2020
Infection, Immunity and Inflammation, Institute of Child Health, University College London, London, UK.
Comment on: Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections.
J Antimicrob Chemother
September 2020
Bristol Centre for Antimicrobial Research & Evaluation, Infection Sciences, Southmead Hospital, Bristol BS10 5NB, UK.
Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections.
J Antimicrob Chemother
January 2020
Infection, Immunity and Inflammation, Institute of Child Health, University College London, London, UK.
Background: β-Lactam (BL)/β-lactamase inhibitor (BLI) combinations are widely used for the treatment of Gram-negative infections. Cefepime has not been widely studied in combination with BLIs. Sulbactam, with dual BL/BLI activity, has been partnered with very few BLs.
View Article and Find Full Text PDFIn vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.
Int J Antimicrob Agents
June 2004
Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
The resistance rates of ampicillin/sulbactam 2:1 against imipenem-susceptible and -resistant Acinetobacter baumannii were 23.5 and 30%, respectively. Ceftazidime/sulbactam combination showed significant reduction of resistant rates against Enterobacter cloacae, A.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!